| text only |
|
|||||||||||||||||||||||||||||
Professional Profile
Research Interests: -Chemokine signaling in cancer progression, angiogenesis and metastasis. -Cancer stem cells Honors and Academic Achievements: -First ranking in M.S. (Pathology and Microbiology), Aligarh M. University, Aligarh, India, (1994) -Junior/Senior Research Fellowships, Central Inst. Med. Aromat. Pl. (CIMAP), Lucknow, India (1996-2001) -Second place in Science debate, Central Inst. Med. Aromat. Pl. (CIMAP), Lucknow, India, (1997) -Paper published in British Journal of Cancer selected for press release by Cancer Research, U.K., (2009) Education: -Ph.D., Aligarh M. University, India, Botany, Pathology & Microbiology, (2001) -M.S., Aligarh M. University, India, Botany, Pathology and Microbiology, (1994) -B.S., Aligarh M. University, India, Botany, Chemistry, Zoology, (1992) Professional Appointments: -Member, USA Mitchell Cancer Institute, 2009-present Scientific Focus: Chemokines are a large group of low molecular weight cytokines, whose primary function is to serve as leukocyte attractants. However, recent evidence indicates that chemokines also play a role in a number of tumor-related processes [Cancer Meta. Rev. 26(3-4):453-67, 2007]. Chemokines bind to G-coupled, seven trans-membrane spanning cell-surface receptors (GPCR) to activate downstream cell signaling. Importantly, several recent studies have also identified chemokines as markers for “cancer stem cells” [Clin Exp Metastasis. 25(1):11-32, 2008; Cancer Res. 69(4):1302-13, 2009]. Our work has demonstrated multiple pathological implications of two chemokine receptors, CXCR1 and CXCR2, in melanoma growth, angiogenesis and metastasis [Brit. J. Cancer. 100(10):1638-46, 2009]. We have shown that targeting CXCR1/2 using small molecule inhibitors can repress melanoma growth and progression indicating a potential therapeutic benefit [Clin. Cancer Res. 15(7):2380-6, 2009]. Our laboratory is currently focused on identifying the precise downstream signaling elicited by CXCR1/2 upon CXCL8 ligand binding, defining cross-talk with other cell signaling pathways, and investigating the pathological significance of CXCR1/2 and other chemokine receptors in gynecological malignancies. Selected Publications: 1. Singh S., Sadanandam, A., and Singh, R.K. (2007). Chemokines in tumor angiogenesis and metastasis. Cancer Meta. Rev. 26(3-4): 453-467. 2. Singh, S., Varney, M.L., and Singh, R.K. (2009). Host CXCR2-dependent regulation of melanoma growth, angiogenesis and experimental lung metastasis. Cancer Res. 69(2): 411-415. 3. Singh, S., Sadanandam, A., Varney, M.L., Mayer-Ezel, R., Bond, R. and Singh, R.K. (2009). Small molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival and angiogenesis. Clin. Cancer Res. 15(7): 2380-2386. 4. Singh, S., Nannuru, K., Sadanandam, A., Varney, M.L., and Singh, R.K. (2009). CXCR1 and CXCR2 enhance human melanoma tumorigenesis, growth and invasion. Brit. J. Cancer 100(10):.1638-1646. 5. Singh, S., Zahid, M., Saeed, M., Gaikwad, N.W., Meza, J.L., Cavalieri, E.L., Rogan, E.G., and Chakravarti, D. (2009). NAD(P)H:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphisms imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells. J Steroid Biochem Mol Biol. Jul 20. (In press). Patents: -U.S. Patent # 20020076802 (2000). Novel streptomyces strain with potential antimicrobial activity against phyto-pathogenic fungi. |
||||
Seema Singh, Ph.D.University of South Alabama - Mobile Alabama 36688-0002 Appointments: Medical, Surgical and Gynecologic Oncology: (251) 665-8000 Radiation Oncology: (251) 445-9615 Administration: (251) 460-6993 For questions or comments Contact Us Date last changed: October 15, 2009 9:41 AM http://www.southalabama.edu/mci/ssingh.html |
 |